Kardigan, Inc. SEC filings KARD
Kardigan, Inc. has 54 filings in SEC EDGAR's recent list, going back to Mar 26, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 30, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 30, 2026 | Sep 29, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jun 23, 2026 | Jun 22, 2026 |
| 424B4 | Prospectus | Jun 18, 2026 | — |
| EFFECT | Filing | Jun 17, 2026 | — |
| S-1MEF | Filing | Jun 17, 2026 | — |
| S-8 | Employee stock plan registration | Jun 17, 2026 | — |
| CERT | Filing | Jun 17, 2026 | — |
| 8-A12B | Filing | Jun 15, 2026 | — |
| S-1/A | Amended registration statement | Jun 11, 2026 | — |
| S-1 | Registration statement | May 26, 2026 | — |
| DRS/A | Filing | May 4, 2026 | — |
| DRS | Filing | Mar 26, 2026 | — |
Showing 14 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KARD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2123613
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.